WAVE LIFE SCIENCES LTD (WVE)
Health Care · Biotechnology · NASDAQ
Wave Life Sciences is a clinical-stage biotech company developing stereopure nucleic acid therapeutics via its proprietary PRISM platform to treat genetically defined diseases.
What WAVE LIFE SCIENCES LTD does
Wave Life Sciences is a clinical-stage biotechnology company focused on developing genetic medicines for patients with serious, genetically defined diseases. The company utilizes its proprietary PRISM platform to design and manufacture stereopure nucleic acid therapeutics, including oligonucleotides, with the goal of improving therapeutic outcomes.
Themes: genetic medicine, nucleic acid therapeutics, oligonucleotides, rare disease therapeutics
Fundamentals
- Price$5.29 as of 2026-08-21 close
- Market cap$1.0B as of 2026-08-21
- 1-year return-45.8% 2025-08-21 close $9.76 → 2026-08-21 close $5.29
- P/En/a negative earnings
- Net margin-309.7% as of 2026-08-24
- ROE-49.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-30.4% as of 2026-08-24
- Revenue CAGR (3y)+127.1% SEC XBRL
- Beta-1.50 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How WVE compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How WAVE LIFE SCIENCES LTD looks technically
WAVE LIFE SCIENCES LTD (WVE) is trading 44.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 77 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It made a new 20-day low about 9 trading days ago. It is 75.7% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 44.1% below its 200-day average, the long-term trend line — a long-term downtrend | -44.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.81 | $5.81 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.46 | $9.46 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 77 trading days ago — a "death cross", a bearish long-term signal | 77 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend) | 24.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 42.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($5.01 to $6.41) — its "stochastic" reading is 20 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 20.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $21.73 | $21.73 |
|---|---|---|
| From the 52-week high | it is 75.7% below its 52-week high (its highest price of the past year) | -75.7% |
| Above the 52-week low | it is 5.6% above its 52-week low (its lowest price of the past year) | +5.6% |
| Below the 52-week high | it is 75.7% below its highest point of the past year | 75.7% |
| Since a 20-day breakout | it made a new 20-day low about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day low about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $56.00 (set on 2018-09-24) | $56.00 |
| Given back of the 52-week move | over the past year its closes ranged ($5.04 to $21.31), and it has recovered essentially none of its fall from last year’s high — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $15.10 to $15.62. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.5% |
| From the all-time high | it is 90.6% below its all-time high | -90.5% |
| Nearest price level | it is trading 1.0% below a resistance level at $5.34 — a price it turned at four times since 2024-09-23, most recently on 2026-08-03. Since 2024-08-21 it has 1 such level below the current price and 17 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.0% |
| All-time low | its lowest closing price on record is $1.16 (set on 2022-05-13) | $1.16 |
| Above the all-time low | it is 356.0% above its all-time low | +356.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 76% of it) | 76th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3202 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3202 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.90 and $6.30 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.90 – $5.60 – $6.30 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 13.0 daily ranges below its 200-day average price (44.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 13.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.96× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.9% |
|---|---|---|
| Open gap | it gapped 4.9% above the previous close 7 sessions ago and has not traded back through the level it left behind at 5.05 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.9% |
| Gap filled | a 5.1% gap up opened on 2026-08-10 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 11.0 percentage points (the stock lost 8.6% while the market gained 2.3%) | -11.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 20.7 percentage points (the stock lost 17.6% while the market gained 3.1%) | -20.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 71.9 percentage points (the stock lost 60.8% while the market gained 11.1%) | -71.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 66.3 percentage points (the stock lost 45.8% while the market gained 20.5%) | -66.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -11.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 39% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $8.64 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -38.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $5.47 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | -3.4% |
Price levels it has turned at before
WVE last closed at $5.29 on 2026-08-21. Since 2024-08-21 it has turned at 1 price below its last close and 17 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.34 | Resistance | 1.0% above the last close | turned there four times · 2024-09-23 to 2026-08-03 |
| $5.53 | Resistance | 4.6% above the last close | turned there twice · 2026-06-29 to 2026-07-17 |
| $5.02 | Support | 5.0% below the last close | turned there three times · 2024-09-06 to 2026-08-11 |
| $6.13 | Resistance | 16.0% above the last close | turned there twice · 2024-09-09 to 2026-07-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · lagging the market · Printed a doji candle · Most volatile (6%+ typical daily range) · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.13 mean, 1=Strong Buy…5=Strong Sell) — 16 analysts
- Mean price target$19.06 range $12.00 – $42.00; median $15.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for WVE
- Consensus EPS estimate-$0.317 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial failure and the inability to demonstrate therapeutic benefits of stereopure candidates.","Significant need for additional capital to fund ongoing operations and research and development.","Dependence on the successful development and regulatory acceptance of the relatively new class of nucleic acid therapeutics."]
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 4 sells ($135072) — 4 selling insiders
- Last 90 days0 buys · 4 sells ($135072) — 4 selling insiders
- Last 180 days4 buys ($55M) · 6 sells ($634665) — 1 buying, 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-12. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about WVE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
WVE had 16,401,737 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
WVE had 8.32% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.45 days to cover at the same settlement.
- Reported short interest (shares) 16,401,737
- Short interest (% of shares outstanding) 8.32%
- Prior settlement (shares) 16,848,760
- Reported change -2.65%
- Days to cover (reported) 7.45
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ionis Pharmaceuticals (IONS)
- Alnylam Pharmaceuticals (ALNY)
- Sarepta Therapeutics (SRPT)
- Arrowhead Pharmaceuticals (ARWR)
- Biogen (BIIB)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare WVE vs…
WAVE LIFE SCIENCES LTD is found in…
Frequently asked questions
What does WAVE LIFE SCIENCES LTD (WVE) do?
Wave Life Sciences is a clinical-stage biotechnology company focused on developing genetic medicines for patients with serious, genetically defined diseases. The company utilizes its proprietary PRISM platform to design and manufacture stereopure nucleic acid therapeutics, including oligonucleotides, with the goal of improving therapeutic outcomes.
What sector is WAVE LIFE SCIENCES LTD (WVE) in?
WAVE LIFE SCIENCES LTD (WVE) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are WAVE LIFE SCIENCES LTD's (WVE) competitors?
Notable peers of WAVE LIFE SCIENCES LTD (WVE) include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Arrowhead Pharmaceuticals and Biogen. This peer set is informational only — not financial advice.
Is WAVE LIFE SCIENCES LTD (WVE) overbought or oversold right now?
WAVE LIFE SCIENCES LTD (WVE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on WVE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.